The inhalation company Inhalation Sciences reports lower revenue in the fourth quarter compared with the same period a year earlier. The operating loss increased.Revenue fell 13.3 percent to 1.3 million kronor (1.5).The operating result was -2.7 million kronor (-2.4). The result after tax was -2.6 million kronor (-2.4). Earnings per share amounted to -0.07 kronor (-0.16). Order intake came in at 5.4 million kronor (0.9), an increase of 500 percent year-on-year. The order backlog at the end of the period was 5.8 million (0.6)."The fourth quarter ended with several of our ongoing discussions being converted into larger product and IRS assignments worth over 5 million kronor. This reflects months of discussions that have finally borne fruit, as both our existing and new customers recognize the value of our unique technology versus the existing alternatives. This also means that we begin 2026 with a large order backlog, which compensates for part of the relatively low revenue during 2025", says CEO Manoush Masarrat.Inhalation Sciences, MSEKQ4-2025Q4-2024ChangeOrder intake5.40.9500.0%Net sales1.31.5-13.3%Operating result-2.7-2.4Net result-2.6-2.4Earnings per share, kronor-0.07-0.16